Trader: Time To Get...
Health Care: Drugs
Nektar Therapeutics Inc. (NKTR: NASDAQ)
$7.00 0.03 | 0.43%
05/24/12 - 04:00 PM ET
925.71K / 1.27M
Vol / Avg. Vol:6.98 / 6.97
Open / Prev. Close:6.78 - 7.01
Today's Range:4.07 - 9.71
52 Wk Range:24.58%
Performance YTD:TheStreet Rating:
Portfolios with NKTR
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- Contributor10 Health Care Stocks With ...
- Contributor10 Mid-Caps With Upside
- Contributor10 Pharma Stocks With Upside
- ProDriehaus Capital
- UserSUPRATRADE 7 Top Stocks for...
- UserSUPRATRADE 10 Stock Picks F...
- UserASCO 2010
- UserPART 3 JPMorgan 28th Annual...
- UserBVF Inc.
Latest NKTR Headlines from TheStreet
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- Signs Point to MAP Pharma Drug Rejection 03.26.12 | 04:03 pm
- Nektar Stock Hits New 52-Week Low (NKTR) 11.16.11 | 12:11 pm
- Nektar Bulls Fight Through Pain 10.04.11 | 08:10 am
- Nektar Stock Hits New 52-Week Low (NKTR) 10.03.11 | 10:10 am
- Nektar Stock Hits New 52-Week Low (NKTR) 08.03.11 | 10:08 am
- Nektar Stock Hits New 52-Week Low (NKTR) 07.26.11 | 10:07 am
- Nektar Stock Hits New 52-Week Low (NKTR) 06.24.11 | 02:06 pm
- Stocks Under $5: Stealth Stock on Sale
06.16.11 | 06:06 am - Nektar Stock Hits New 52-Week Low (NKTR) 06.14.11 | 03:06 pm
Press Releases for NKTR
- Nektar To Host Investor And Analyst R&D Day In New York City - PR Newswire 04.10.12 | 08:04 am
- Nektar Doses First Subjects In Phase 1 Clinical Study Evaluating NKTR-192, A New Short-Acting Opioid Molecule For The Treatment Of Acute Pain - PR Newswire 04.02.12 | 08:04 am
- Nektar Consolidates Research At Its State-of-the-Art R&D Center Located In San Francisco At Mission Bay - PR Newswire 03.20.12 | 10:03 am
- Nektar Therapeutics Announces Webcast Of Presentation At The 32nd Annual Cowen And Company Healthcare Conference In Boston - PR Newswire 03.02.12 | 09:03 pm
- Nektar Presents Positive Proof-of-Concept Clinical Data For Its New Opioid Molecule, NKTR-181, At American Academy Of Pain Medicine's 28th Annual Meeting - PR Newswire 02.27.12 | 08:02 am
- Nektar To Announce Financial Results For The Fourth Quarter And Year-End Of 2011 On Wednesday, February 29, 2012, After Close Of U.S.-Based Financial Markets - PR Newswire 02.24.12 | 07:02 pm
- Baxter Initiates Phase I Clinical Trial Of Longer-acting Recombinant FVIII Treatment For Hemophilia A - PR Newswire 01.05.12 | 09:01 am
- Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 30th Annual J.P. Morgan Healthcare Conference In San Francisco, CA - PR Newswire 01.04.12 | 06:01 pm
- Nektar Announces Positive Clinical Data From Second Phase 1 Clinical Study Of NKTR-181, A Novel Opioid Analgesic Molecule To Treat Chronic Pain - PR Newswire 12.13.11 | 07:12 am
- Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The UBS 2011 Global Life Sciences Conference In New York City - PR Newswire 09.14.11 | 08:09 pm
Partner Headlines for NKTR
- Long Undervalued, Is Alkermes Still A Bargain? - Seeking Alpha 03.30.12 | 09:03 am
- The Age Of Personalized Medicine Has Arrived - Seeking Alpha 03.08.12 | 09:03 am
- Company News for March 1, 2012 - Corporate Summary - Zacks 03.01.12 | 10:03 am
- What's It Going To Take To Get Salix Cheap? - Seeking Alpha 02.29.12 | 08:02 am
- Nektar Therapeutics Presents Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer - Benzinga 09.10.11 | 04:09 pm
- 10 Stocks With Bullish Momentum Backed By Strong Top Line Growth - Seeking Alpha 08.24.11 | 08:08 am
- 14 Oversold Stocks Trading Near Lows but Being Bought Up by the Smart Money - Seeking Alpha 07.12.11 | 09:07 am
- Are These 10 Sick Healthcare Companies Terminally Ill? - Seeking Alpha 07.07.11 | 09:07 am
- Arthur Cohen and Joseph Healey's Successful Stock Picks - Seeking Alpha 05.23.11 | 08:05 am
- Company News for May 18, 2011 - Corporate Summary - Zacks 05.18.11 | 10:05 am
